BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Wang N, Shao L, Lu W, Fang W, Zhang Q, Sun L, Gao S, Zhu Q, Chen S, Hu R. 5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis. Journal of Drug Delivery Science and Technology 2022;74:103578. [DOI: 10.1016/j.jddst.2022.103578] [Reference Citation Analysis]
2 Zhong Y, Xiao Q, Kang Z, Huang J, Ge W, Wan Q, Wang H, Zhou W, Zhao H, Liu D. Astragalus polysaccharide alleviates ulcerative colitis by regulating the balance of Tfh/Treg cells. Int Immunopharmacol 2022;111:109108. [PMID: 35926271 DOI: 10.1016/j.intimp.2022.109108] [Reference Citation Analysis]
3 Li H, Wang Y, Shao S, Yu H, Wang D, Li C, Yuan Q, Liu W, Cao J, Wang X, Guo H, Wu X, Wang S. Rabdosia serra alleviates dextran sulfate sodium salt-induced colitis in mice through antiinflammation, regulating Th17/Treg balance, maintaining intestinal barrier integrity, and modulating gut microbiome. Journal of Pharmaceutical Analysis 2022. [DOI: 10.1016/j.jpha.2022.08.001] [Reference Citation Analysis]
4 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
5 Li N, Zhan S, Liu C, Li T, Tu T, Chen B, He Y, Chen M, Zeng Z, Zhuang X. Development and validation of a nomogram to predict indolent course in patients with ulcerative colitis: a single-center retrospective study. Gastroenterol Rep (Oxf) 2022;10:goac029. [PMID: 35785264 DOI: 10.1093/gastro/goac029] [Reference Citation Analysis]
6 Guo Y, Li Y, Cao Q, Ye L, Wang J, Guo M. The Function of Natural Polysaccharides in the Treatment of Ulcerative Colitis. Front Pharmacol 2022;13:927855. [DOI: 10.3389/fphar.2022.927855] [Reference Citation Analysis]
7 Zhong Y, Liu W, Xiong Y, Li Y, Wan Q, Zhou W, Zhao H, Xiao Q, Liu D. Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells. Phytomedicine 2022;104:154287. [PMID: 35752072 DOI: 10.1016/j.phymed.2022.154287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhong Y, Xiao Q, Li S, Chen L, Long J, Fang W, Yu F, Huang J, Zhao H, Liu D. Bupi Yichang Pill alleviates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the homeostasis of follicular helper T cells. Phytomedicine 2022;100:154091. [PMID: 35395566 DOI: 10.1016/j.phymed.2022.154091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hu Y, Ye Z, She Y, Li L, Wu M, Qin K, Li Y, He H, Hu Z, Yang M, Lu F, Ye Q. Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Front Pharmacol 2022;13:844961. [DOI: 10.3389/fphar.2022.844961] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Li Z, Gao Y, Du L, Yuan Y, Huang W, Fu X, Huang Y, Zhang X, You F, Li S. Anti-inflammatory and anti-apoptotic effects of Shaoyao decoction on X-ray radiation-induced enteritis of C57BL/6 mice. J Ethnopharmacol 2022;:115158. [PMID: 35245630 DOI: 10.1016/j.jep.2022.115158] [Reference Citation Analysis]
11 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
12 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Kim G, Jang M, Hwang I, Cho J, Kim S. Radish sprout alleviates DSS-induced colitis via regulation of NF-kB signaling pathway and modifying gut microbiota. Biomed Pharmacother 2021;144:112365. [PMID: 34794235 DOI: 10.1016/j.biopha.2021.112365] [Reference Citation Analysis]
14 Suárez-cruz A, Molina-pinilla I, Hakkou K, Rangel-núñez C, Bueno-martínez M. Novel poly(azoamide triazole)s containing twin azobenzene units in the backbone. Synthesis, characterization, and in vitro degradation studies. Polymer Degradation and Stability 2021;193:109726. [DOI: 10.1016/j.polymdegradstab.2021.109726] [Reference Citation Analysis]
15 Zhong Y, Kang Z, Wang M, Long J, Wang H, Huang J, Wei S, Zhou W, Zhao H, Liu D. Curcumin ameliorated dextran sulfate sodium-induced colitis via regulating the homeostasis of DCs and Treg and improving the composition of the gut microbiota. Journal of Functional Foods 2021;86:104716. [DOI: 10.1016/j.jff.2021.104716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Deissler H, Krammer H, Gillessen A. pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). Biomed Rep 2021;15:96. [PMID: 34631051 DOI: 10.3892/br.2021.1472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Bakulin IG, Skalinskaya MI, Maev IV, Skazyvaeva EV, Zhuravleva MS, Gaikovaya LB, Bakulina NV, Ermakov AI, Alekseenko ES, Ivanova KN, Solovev MV. Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management. Terapevticheskii arkhiv 2021;93:841-52. [DOI: 10.26442/00403660.2021.08.200982] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bernstein CN, Tenakoon A, Singh H, Targownik LE. Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study. Aliment Pharmacol Ther 2021;54:814-32. [PMID: 34247410 DOI: 10.1111/apt.16518] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Correia JP, Ponte AI, Silva JC, Gomes AC, Afecto E. Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:595. [PMID: 33657605 DOI: 10.1097/MEG.0000000000001901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ahmad A, Ansari MM, Mishra RK, Kumar A, Vyawahare A, Verma RK, Raza SS, Khan R. Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis. Materials Science and Engineering: C 2021;119:111582. [DOI: 10.1016/j.msec.2020.111582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
21 Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S. 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. Curr Drug Targets 2021;22:117-25. [PMID: 32718289 DOI: 10.2174/1389450121666200727120305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
25 Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther 2020;20:407-12. [PMID: 31847610 DOI: 10.1080/14712598.2020.1701652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]